

## [Opto Circuits' Consolidated Net Sales at Rs. 715 cr, Net Profit at Rs. 138 cr](#)

Bengaluru, India | August 14, 2012

The Board of Directors of Opto Circuits (India) Ltd. (OCI), a leading developer and manufacturer of medical equipment and interventional devices for the global markets, today approved and announced the financial results for the first quarter of FY13.

### Consolidated Financial Highlights:

Items	Q1FY13	Q1FY12	Growth
Net Sales (Rs. cr.)	715	521	37%
EBITDA (Rs. cr.)	193	148	30%
EBITDA (% to Net Sales)	27%	28%	-
PAT (Rs. cr.)	138	116	19%
PAT (% to Net Sales)	19%	22%	-
EPS (Rs.)	5.70	4.80	19%

For Q1FY13, Medical Equipment contributed 82% to turnover, Interventional Devices contributed 18% and non medical businesses contributed 1%.

### Management Comments:

Vinod Ramnani, Chairman and Managing Director, OCI comments:

“Both our businesses have performed in line with our expectations during the quarter. Our focus on emerging markets is paying off and is reflecting in our revenue growth. From this quarter onwards, the Board has approved the expensing out of all product development costs of Opto Cardiac Care Ltd. This is an accounting change reflective of our endeavour to comply with international standards of R&D accounting. I am also happy to report that just today, we started the international shipments of Powerheart® G5, our next generation AED. I am confident that this product will gain global market leadership in the next few months.”

### Business Highlights:

#### Medical Equipment & Consumables:

Cardiac Science Corporation launched its CE-certified Powerheart® G5 AED, the next-generation, CPR assistance AED in Europe to help save lives from sudden cardiac arrest (SCA).

Cardiac Science Corporation entered into a contract with 2012 UEFA European Football Championship to supply its trusted Powerheart AEDs to venues involved in the international tournament in Ukraine, including stadiums, team accommodations, airports and railway stations. Our company AEDs were also deployed at the London Olympics 2012.

NSE symbol:  
OPTOCIRCUI

BSE code: 532391

Headquarters:  
Bengaluru

Market Cap:  
Rs. 3738 crs \*  
\*As on 29<sup>th</sup> June 2012  
as per the BSE closing price

Consolidated FY2012  
numbers:  
Net Sales - Rs. 2357 crs  
Net Profit - Rs. 572 crs  
EPS - Rs. 23.6

Group Patents:  
193 (+ 108 pending applications)

Group Employee  
Strength: ~1840

Continuing our Heart-safe awareness campaign, we presented our patented US FDA approved Powerheart® G3 Plus Automated External Defibrillator (AED) to India Habitat Centre, rendering it Heart-safe.

AMDL Health, the healthcare division of our subsidiary - AMDL, deployed the Powerheart® G3 AEDs at the Bengaluru International Airport (BIAL).

### Interventional Devices & Tools:

Eurocor's Valentines Trial II Global Registry was presented by Dr. Antonio Serra at EuroPCR 2012 in Paris. The eight-month results convincingly show that the DIOR® DEB is a safe and effective treatment for cases of de novo lesions.

### About: Opto Circuits (India) Limited

Opto Circuits (India) Ltd. is an India-headquartered multinational medical devices company. OCI is in the business of designing, developing, manufacturing and marketing of healthcare equipment and medical interventional products. A leader in cardiac and vital signs monitoring, emergency cardiac care, vascular treatments and sensing technology, most of Opto Circuits' products are USFDA listed and CE marked and are marketed in over 150 countries. Known for its industry leading performance in advanced critical care and therapeutic medical devices, Opto Circuits business performance has been ranked in *Forbes' Asia's 200 Best under a Billion* in 2008, 2009 and 2011. Some of the Company's well-known brands are Cardiac Science, Criticare, Eurocor, Ormed, Mediaid and Unetixs. For more information, please visit [www.optocircuits.com](http://www.optocircuits.com).

### Contact Us:

Opto Circuits (India) Ltd.

E: Media - [media@optoindia.com](mailto:media@optoindia.com) | Investors - [ir@optoindia.com](mailto:ir@optoindia.com)

T: +91 80 28528088

Adfactors PR

Neha Goenka

E: [neha.goenka@adfactorspr.com](mailto:neha.goenka@adfactorspr.com)

T: +91 22 2281 3565

### Disclaimer:

Statements made in this Press Release describing the company's objectives, projections, estimates, expectations may be "Forward-looking Statements" within the meaning of all applicable laws and regulations. Actual results could differ from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting demand, supply and price conditions in the domestic and overseas markets in which the Company operates changes in government regulations, tax laws, other statutes and other incidental factors.

###

NSE symbol:  
OPTOCIRCU

BSE code: 532391

Headquarters:  
Bengaluru

Market Cap:  
Rs. 3738 crs \*  
\*As on 29<sup>th</sup> June 2012  
as per the NSE closing  
price

Consolidated FY2012  
Highlights:  
Net Sales - Rs. 2357 crs  
Net Profit - Rs. 572 crs  
EPS - Rs. 23.6

Group Patents:  
193 (+ 108 pending  
applications)

Group Employee  
Strength: ~1840